Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XiaoJiYin plus erlotinib in advanced non-small cell lung cancer patients unsuitable for chemotherapy
ChiCTR-ONRC-13003416Phase 4Recruiting
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of erlotinib and XiaoJiYin in non-small cell lung cancer (NSCLC), sponsored by Guangdong Provincial Hospital of Traditional Chinese Medicine. Primary endpoints: overall survival, 1-year survival rate and 2 more. Started Jul 2014; status: recruiting.
02
Drugs
erlotinibXiaoJiYin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-ONRC-13003416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONRC-13003416.